What are the differences between acute, subacute, and chronic infective endocarditis regarding clinical presentation, typical causative organisms, and recommended antimicrobial therapy?

Acute vs Subacute vs Chronic Endocarditis

Acute endocarditis presents over days with high fevers (>102°F), is caused by highly virulent organisms like S. aureus and β-hemolytic streptococci, and requires empirical coverage for these aggressive pathogens, while subacute endocarditis develops over weeks with lower-grade symptoms, is typically caused by viridans group streptococci (VGS), S. gallolyticus, and enterococci, requiring different antimicrobial coverage 1, 2.

Clinical Presentation

Acute Endocarditis (Days)

• Fulminant illness with high fevers (temperature >102°F)
• Rapid progression with severe systemic toxicity
• Septic embolic phenomena are characteristic
• Acute valve dysfunction and congestive heart failure develop quickly
• Patients appear acutely ill with obvious sepsis 2

Subacute Endocarditis (Weeks)

• Indolent course with lower-grade fevers
• Fever present in 86% of cases, heart murmur in 81%
• Dyspnea occurs in 46% of patients
• Cardiac abscess/pseudoaneurysm in 18%, embolic events in 25%
• Patients may have prolonged symptom duration before diagnosis 3, 4
• Often presents with nonspecific symptoms like malaise, night sweats, and weight loss

Chronic Endocarditis

• Rare presentation, typically associated with low-virulent pathogens (fungi, Coxiella burnetii, Brucella)
• Results from inefficient antibacterial therapy or fastidious organisms
• Progressive immune-mediated complications: nephritis, vasculitis, synovitis, polyserositis 5

Causative Organisms

Acute Endocarditis

• Staphylococcus aureus (most common)
• β-hemolytic streptococci (Groups A, B, C, F, G)
• Aerobic Gram-negative bacilli
• Occasionally Listeria and Brucella 1, 2

Subacute Endocarditis

• Viridans group streptococci (VGS) - most common, particularly S. mitis/oralis (21%)
• Streptococcus gallolyticus (bovis) (17%)
• Enterococci
• HACEK organisms
• Coagulase-negative staphylococci 1, 4

Chronic Endocarditis

• Fungi (Candida, Aspergillus, Histoplasma)
• Coxiella burnetii (Q fever)
• Bartonella species
• Brucella species
• Other fastidious organisms (Legionella, Mycoplasma) 6, 7, 5

Antimicrobial Therapy

Acute Native Valve Endocarditis (Empirical)

For patients with acute (days) clinical presentations, coverage for S. aureus, β-hemolytic streptococci, and aerobic Gram-negative bacilli is reasonable 1:

• Vancomycin 30 mg/kg/24h IV in 2 divided doses (for MRSA coverage)
• Plus gentamicin 3 mg/kg/24h IV
• Plus a β-lactam (nafcillin, oxacillin, or ceftriaxone depending on local resistance patterns)

Subacute Native Valve Endocarditis (Empirical)

For patients with subacute (weeks) presentation, coverage of S. aureus, VGS, HACEK, and enterococci is reasonable 1:

• Ampicillin 2g IV every 4 hours
• Plus gentamicin 3 mg/kg/24h IV
• Or vancomycin 30 mg/kg/24h IV in 2 divided doses (if β-lactam intolerant)

Targeted Therapy for VGS (Penicillin-Susceptible, MIC ≤0.12 μg/mL)

• Penicillin G 24 million units/24h IV continuously or in 4-6 divided doses for 4 weeks
• Or ceftriaxone 2g/24h IV for 4 weeks
• Gentamicin 3 mg/kg/24h for 2 weeks can be added but not required for highly susceptible strains 1

Targeted Therapy for VGS (Penicillin-Resistant, MIC ≥0.5 μg/mL)

Treat as enterococcal endocarditis with infectious diseases consultation 1:

• Ampicillin or penicillin 24 million units/24h IV
• Plus gentamicin 3 mg/kg/24h for entire duration (4-6 weeks)

Prosthetic Valve Endocarditis

• If <1 year post-surgery: Cover staphylococci, enterococci, and aerobic Gram-negative bacilli
• If >1 year post-surgery: Cover staphylococci, VGS, and enterococci
• Duration: 6 weeks minimum for all prosthetic valve infections 1

Chronic/Fastidious Organisms

Specific regimens based on pathogen 6:

• Brucella: Doxycycline + cotrimoxazole + rifampin for ≥3-6 months
• C. burnetii (Q fever): Doxycycline + hydroxychloroquine for >18 months
• Bartonella: Doxycycline + gentamicin for 4-6 weeks
• Fungi: Antifungal therapy + surgical valve replacement (mortality >50%)

Critical Clinical Pitfalls

Acute endocarditis is suspected on admission in only 23% of cases 3. Clinicians must maintain high suspicion when patients present with:

• Unexplained fever + new heart murmur
• Fever + known valve disease or prosthetic valve
• Fever + recent invasive procedure
• Septic emboli (stroke, splenic infarct, peripheral emboli)

Key differentiator: Acute presentations have shorter symptom duration, while subacute cases have longer prodromal periods with nonspecific symptoms that delay diagnosis 3.

Always obtain 3 sets of blood cultures at 30-minute intervals before initiating antibiotics 6. However, do not delay treatment in acutely ill patients—draw cultures quickly and start empirical therapy immediately.

Infectious diseases consultation is recommended for all culture-negative endocarditis cases and for penicillin-resistant VGS requiring enterococcal-type regimens 1.